Aucune différence significative du taux de poussée chez les patients passant au natalizumab administré une fois toutes les 6 semaines ou restant sous natalizumab administré une fois toutes les 4 semaines : analyse d’efficacité comparative de l’étude TOP

Translated title of the contribution: No significant difference in relapse rates in patients switching to natalizumab given once every 6 weeks or remaining on natalizumab administered once every 4 weeks: comparative efficacy analysis of the TOP study

Helmut Butzkueven, Ludwig Kappos, Tim Spelman, Maria Trojano, Heinz Wiendl, Ray Su, Robert Hyde, Stephanie Licata, Pei Ran Ho, Nolan Campbell

Research output: Contribution to journalMeeting AbstractOtherpeer-review

Translated title of the contributionNo significant difference in relapse rates in patients switching to natalizumab given once every 6 weeks or remaining on natalizumab administered once every 4 weeks: comparative efficacy analysis of the TOP study
Original languageFrench
Pages (from-to)S124
Number of pages1
JournalRevue Neurologique
Volume176
Issue numberSupplement
DOIs
Publication statusPublished - 1 Sep 2020

Keywords

  • Natalizumab
  • Q6W
  • Étude TOP

Cite this